| Patent Number |
Title Of Patent |
Date Issued |
| 5985317 |
Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical a |
November 16, 1999 |
| A method of transdermally or transmucosally delivering a hydrophilic salt form of a drug with a water-based pressure sensitive hydrophobic adhesive matrix patch optionally containing a permeation enhancer is disclosed. A matrix patch comprising a water-based pressure sensitive hydrophobi |
| 5952000 |
Fatty acid esters of lactic acid salts as permeation enhancers |
September 14, 1999 |
| A transdermal drug delivery system which enhances the delivery of the drug comprises a composition containing, as an enhancer, one or more C.sub.6 to C.sub.22 fatty acid esters of a lactic acid salt. These compositions are made up of a safe and effective amount of an active pharmaceutica |
| 5912009 |
Fatty acid esters of glycolic acid and its salts |
June 15, 1999 |
| A transdermal drug delivery system which enhances the delivery of the drug comprises a composition containing, as an enhancer, one or more C.sub.6 to C.sub.22 fatty acid esters of glycolic acid and its salts. These compositions are made up of a safe and effective amount of an active |
| 5863555 |
Buccal delivery of glucagon-like insulinotropic peptides |
January 26, 1999 |
| Drug delivery systems and methods for administering a glucagon-like insulinotropic peptide to the buccal mucosa for transmucosal drug delivery are described. The drug delivery systems comprise a drug composition containing an effective amount of the glucagon-like insulinotropic peptide |
| 5849322 |
Compositions and methods for buccal delivery of pharmaceutical agents |
December 15, 1998 |
| A composition for transmucosally administering a drug to the oral cavity comprises an adhesive layer comprising a hydrophilic polymer having one surface adapted to contact a first tissue of the oral cavity and adhere thereto when wet and an opposing surface in contact with and adhering t |
| 5834010 |
Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
November 10, 1998 |
| A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pK.sub.a of about 8.0 or greater, an effective amount of a penetration enhancer consi |
| 5783208 |
Transdermal drug delivery matrix for coadministering estradiol and another steroid |
July 21, 1998 |
| A matrix type transdermal patch for coadministering estradiol and another steroid wherein the matrix is composed of a N-vinyl-2-pyrrolidone-containing acrylic copolymer pressure sensitive adhesive, estradiol, the other steroid, and optionally a permeation enhancer, and the respective |
| 5780050 |
Drug delivery compositions for improved stability of steroids |
July 14, 1998 |
| A stabilized patch device for transdermal drug delivery of steroid drugs containing a 3-keto-4-en functional group is described, wherein the patch comprises an effective amount of the steroid drug and a carrier that is free of acid functional groups. The device can further contain additi |
| 5766620 |
Buccal delivery of glucagon-like insulinotropic peptides |
June 16, 1998 |
| Drug delivery systems and methods for administering a glucagon-like insulinotropic peptide to the buccal mucosa for transmucosal drug delivery are described. The drug delivery systems comprise a drug composition containing an effective amount of the glucagon-like insulinotropic peptide |
| 5762953 |
Transdermal propentofylline compositions for the treatment of Alzheimers disease |
June 9, 1998 |
| Patients suffering from Alzheimer's disease are treated by transdermally administering an effective amount of propentofylline in the form of an occulsive device containing a delivery composition comprising a carrier vehicle having uniformly distributed therein effective amounts of pr |
| 5686094 |
Controlled release formulations for the treatment of xerostomia |
November 11, 1997 |
| A polymeric delivery system which is formed by a polycarbophil type composition with an active agent, optionally in the presence of water and/or other cosolvent. The resulting product is especially useful as a carrier or coating of active compositions, such as pharmaceuticals and the |
| 5662925 |
Transdermal delivery system with adhesive overlay and peel seal disc |
September 2, 1997 |
| A device for administering an active agent to the skin or mucosa of an individual comprising a laminated composite of an adhesive overlay, a backing layer underlying the central portion of the adhesive overlay, an active agent-permeable membrane, the backing layer and membrane defining a |
| 5626866 |
Drug-containing adhesive composite transdermal delivery device |
May 6, 1997 |
| A method for making a transdermal drug delivery device for heat sensitive and volatile drugs is disclosed. The device contains a drug-containing adhesive composite layer having an impermeable backing material laminated to the distal surface thereof and a proximal peelable impermeable bac |
| 5601839 |
Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
February 11, 1997 |
| A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pK.sub.a of about 8.0 or greater, an effective amount of penetration enhancer consist |
| 5585464 |
Recombinant antigen for diagnosing rheumatoid arthritis |
December 17, 1996 |
| A method is described for diagnosing rheumatoid arthritis by providing a recombinant antigen (RAMA) and detecting rheumatoid arthritis-associated IgM antibodies against the RAMA antigen in patient sera. The RAMA antigen comprises SEQ ID NO:3 and peptides substantially homologous thereto. |
| 5516523 |
Transmucosal delivery of macromolecular drugs |
May 14, 1996 |
| A method and system for mucosally administering a macromolecular drug to mucosa of the oral cavity is shown. The system comprises an inner drug/enhancer/polymer layer having one surface adapted to contact and adhere to the mucosal tissue of the oral cavity and an opposing surface in |
| 5460820 |
Methods for providing testosterone and optionally estrogen replacement therapy to women |
October 24, 1995 |
| A method of providing testosterone replacement therapy to a woman in need of such therapy comprising applying a testosterone-delivering patch to the skin of said woman which patch transdermally delivers 50 to 500 .mu.g/day of testosterone to the woman. |
| 5445607 |
Iontophoresis device and method using a rate-controlling electrically sensitive membrane |
August 29, 1995 |
| An iontophoresis device comprising a drug reservoir containing the drug in ionic form and in communication with the skin, a skin permeation enhancing agent contained in the reservoir or in a second reservoir also in communication with the skin, an electrode in contact with the drug, |
| 5395753 |
Method for diagnosing rheumatoid arthritis |
March 7, 1995 |
| A method is described for diagnosing rheumatoid arthritis by providing a recombinant IgM-specific rheumatoid arthritis-associated antigen and detecting antibodies against the antigen in patient sera. Preliminary steps of making a cDNA library from polyadenylated RNA purified from human |
| 5346701 |
Transmucosal delivery of macromolecular drugs |
September 13, 1994 |
| A method and system for mucosally administering a macromolecular drug to mucosa of the oral cavity is shown. The system comprises an inner drug/enhancer/polymer layer having one surface adapted to contact and adhere to the mucosal tissue of the oral cavity and an opposing surface in |
| 5336486 |
Appetite control method |
August 9, 1994 |
| A method for suppressing appetite comprising administering by mouth to a subject an amount of polycarbophil that is effective to suppress the appetite of the subject without inducing a laxative effect in said subject. |
| 5302395 |
Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes |
April 12, 1994 |
| Transdermal delivery systems for delivery of nitroglycerin are disclosed which deliver the drug at enhanced transdermal fluxes. The systems include, in addition to nitroglycerin, a permeation enhancer which is either a sorbitan ester, a C.sub.8 -C.sub.22 aliphatic alcohol, or a mixtu |
| 5227169 |
Sorbitan esters as skin permeation enhancers |
July 13, 1993 |
| Skin permeation enhancer compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The compositions contain a sorbitan ester in addition to the selected pharmacologically active agent, and may also contain a C.sub |
| 5212199 |
Sorbitan esters as skin permeation enhancers |
May 18, 1993 |
| Skin permeation enhancer compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The compositions contain a sorbitan ester in addition to the selected pharmacologically active agent, and may also contain a C.sub |
| 5202125 |
Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes |
April 13, 1993 |
| Transdermal delivery systems for delivery of nitroglycerin are disclosed which deliver the drug at enhanced transdermal fluxes. The systems include, in addition to nitroglycerin, a permeation enhancer which is either a sorbitan ester, a C.sub.8 -C.sub.22 aliphatic alcohol, or a mixtu |
| 5164190 |
Subsaturated transdermal drug delivery device exhibiting enhanced drug flux |
November 17, 1992 |
| Transdermal administration of hydrophobic drugs via a diffusion mechanism in which the drug is dissolved in a carrier at concentrations that are 20% to 80% of the saturation concentration. The flux of drug from the device is non-Fickian and is substantially greater than the flux observed |
| 5152997 |
Method and device for transdermally administering testosterone across nonscrotal skin at therape |
October 6, 1992 |
| Testosterone is administered transdermally through nonscrotal skin in a manner that mimics in amount and profile the natural production of testosterone in young adult healthy males. The testosterone is administered to the skin from a matrix which contains testosterone at subsaturatio |
| 5139023 |
Apparatus and method for noninvasive blood glucose monitoring |
August 18, 1992 |
| The present invention is directed to novel methods and apparatus for noninvasive blood glucose monitoring. Blood glucose is monitored noninvasively by correlation with amount of glucose which permeates an epithelial membrane, such as skin or a mucosal membrane, into a glucose receivi |
| 5122383 |
Sorbitan esters as skin permeation enhancers |
June 16, 1992 |
| Skin permeation enhancer compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The compositions contain a sorbitan ester in addition to the selected pharmacologically active agent, and may also contain a C.sub |
| 5041292 |
Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
August 20, 1991 |
| A biodegradable hydrogel matrix is provided, useful for the controlled release of pharmacologically active agents. The matrix is formed by cross-linking a proteinaceous component and a polysaccharide or mucopolysaccharide, and then loading a selected drug therein. By varying temperat |
| 4983395 |
Device for administering an active agent to the skin or mucosa |
January 8, 1991 |
| A transdermal drug delivery device comprising a drug formulation-containing reservoir defined by a backing layer and a drug-permeable membrane layer, a peelable inner liner that underlies the reservoir and a portion of the backing/membrane outwardly of the reservoir periphery, an adhesiv |
| 4925677 |
Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
May 15, 1990 |
| A biodegradable hydrogen matrix is provided, useful for the controlled release of pharmacologically active agents. The matrix is formed by cross-linking a proteinaceous component and a polysaccharide or mucopolysaccharide, and then loading a selected drug therein. By varying temperat |
| 4888354 |
Skin penetration enhancement using free base and acid addition salt combinations of active agent |
December 19, 1989 |
| The invention is directed to compositions for topical application made up of active pharmaceutical permeants capable of existing in both free base and acid addition salt form. The permeants are present as a combination of both free base and acid addition salt forms. These combined forms |
| 4863970 |
Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower a |
September 5, 1989 |
| Penetration-enhancing pharmaceutical compositions for topical transepidermal and percutaneous application are disclosed which are non-irritating to the skin. These compositions are made up of a safe and effective amount of an active pharmaceutical permeant, including hydrophilic salt |
| 4855294 |
Method for reducing skin irritation associated with drug/penetration enhancer compositions |
August 8, 1989 |
| A composition and method for reducing the skin irritation properties of a transdermal drug/enhancer composition which comprises incorporating into said composition, either prior to or at the time of application the skin, an effective amount of glycerin. When incorporated into the drug/en |
| 4849224 |
Device for administering an active agent to the skin or mucosa |
July 18, 1989 |
| A transdermal drug delivery device comprising a drug formulation-containing reservoir defined by a backing layer and a drug-permeable membrane layer, a ring-shaped layer made of an adhesive that is incompatible with one or more components of the drug formulation that is peripheral to the |
